My proposed Mentored Career Development Award in Biomedical Big Data Science (K01) will focus an important but largely unmet need within the field of oncology. Renal cell carcinoma is the 8th most common cancer and the most lethal of the urologic cancers. Systemic medical therapy is required for the 25% of patients who initially present with metastatic disease and 30% of patients who recur following surgery. The selection of which medical treatment to use is not based on biomolecular characteristics of the tumor, despite large variability in the efficacy of th treatments. Only recently, with improvements in sequencing technologies, have these molecular analyses been possible. The research goals proposed within this application combine bioinformatics, biostatistics, and molecular biology to establish an informatics toolkit for investigating the molecular markers of renal cell carcinoma as they relate to treatment success. We hypothesize that building a toolkit into an existing, well-annotated clinical database and tissue repository will allow us to (1) create the first multi-institutional registry of renal cell carcinoma patients with clinical, genomic, and outcomes data, (2) identify molecular predictors of treatment success for existing cancer therapies, and (3) investigate personalized subtypes of patients that correlate with treatment response to immunotherapy. An understanding of molecular predictors of treatment success can have a major impact on decision-making within renal cell carcinoma and establish hypotheses for future clinical trials. Over the course of this Mentored Career Development Award in Biomedical Big Data Science, my goal is to acquire the expertise from my mentors that is required to succeed as an independent investigator, advancing Precision Medicine in renal cell carcinoma through the use of biomedical data science. The 5 years allotted for this project will provide ample time to truly establish the skill necessary for independent research. At least 50% of my time will be devoted solely to research, which will be further supplemented by clinical work involving care for patients with renal cell carcinoma. I have a multi-institutional and multi-disciplinary panel of experts who will guide me through this research project and use the resultant tools. The education that I will receive will b essential in cultivating my ability to use biomedical big data towards improving care in renal cell carcinoma patients. My long-term career goals include pursing additional NIH funding as an independent investigator and lead a multi-disciplinary team in advancing data-driven medicine. In doing so, I hope to inspire future scientists to pursue challenges in biomedical data science and guide them in the same tradition of mentorship that is being given to me.

Public Health Relevance

There currently exists a critical, unmet need to improve methods of selecting effective therapy for advanced kidney cancer, the most lethal of urologic cancers. The proposed mentored career development award will focus on identifying molecular markers of treatment success by developing an informatics toolkit that incorporates molecular data into a large, well-annotated institutional database of patients with advanced kidney cancer. The scientific findings of this grant will be used to identify the most effective treatment based on individual tumor biology and accelerate discovery in the molecular biology of kidney cancer.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Research Scientist Development Award - Research & Training (K01)
Project #
5K01ES026838-02
Application #
9147620
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Shreffler, Carol A
Project Start
2015-09-30
Project End
2020-07-31
Budget Start
2016-08-01
Budget End
2017-07-31
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Urology
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Campbell, Scott P; Baras, Alexander S; Ball, Mark W et al. (2018) Low levels of PSMA expression limit the utility of 18F-DCFPyL PET/CT for imaging urothelial carcinoma. Ann Nucl Med 32:69-74
Chappidi, Meera R; Kates, Max; Stimson, C J et al. (2017) Causes, Timing, Hospital Costs and Perioperative Outcomes of Index vs Nonindex Hospital Readmissions after Radical Cystectomy: Implications for Regionalization of Care. J Urol 197:296-301
An, Julie Y; Ball, Mark W; Gorin, Michael A et al. (2017) Partial vs Radical Nephrectomy for T1-T2 Renal Masses in the Elderly: Comparison of Complications, Renal Function, and Oncologic Outcomes. Urology 100:151-157
Chappidi, Meera R; Chalfin, Heather J; Johnson, Daniel J et al. (2017) Longer average blood storage duration is associated with increased risk of infection and overall morbidity following radical cystectomy. Urol Oncol 35:38.e17-38.e24
Yau, Susanna E; Singer, Eric J; Sun, Yue et al. (2017) Bladder melanosis with concurrent urothelial carcinoma. Urol Case Rep 15:30-32
Patel, Hiten D; Pierorazio, Phillip M; Johnson, Michael H et al. (2017) Renal Functional Outcomes after Surgery, Ablation, and Active Surveillance of Localized Renal Tumors: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol 12:1057-1069
Patel, Hiten D; Iyoha, Emmanuel; Pierorazio, Phillip M et al. (2016) A Systematic Review of Research Gaps in the Evaluation and Management of Localized Renal Masses. Urology 98:14-20
Patel, Hiten D; Gorin, Michael A; Gupta, Natasha et al. (2016) Mortality trends and the impact of lymphadenectomy on survival for renal cell carcinoma patients with distant metastasis. Can Urol Assoc J 10:389-395
Chappidi, Meera R; Kates, Max; Johnson, Michael H et al. (2016) Lymph node yield and tumor location in patients with upper tract urothelial carcinoma undergoing nephroureterectomy affects survival: A U.S. population-based analysis (2004-2012). Urol Oncol 34:531.e15-531.e24